Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1691
This examiner grants 82% of resolved cases
Douglas M. Willis is an examiner in Tech Center 1600 and Art Unit 1624, with 1812 resolved cases. His allowance rate is 82.3 percent. This combination of 1812 cases and the 82.3 percent grant rate provides a statistical profile for practitioners. The allowance rate suggests that a majority of applications he reviews will eventually be granted.
The interview lift for his cases is 19.7 percent. While the base rate is 82.3 percent, interviews still provide a boost to the chances of success. Additionally, the median days to allowance is 687. Applicants can expect a resolution and a likelihood of a grant when their cases are handled by this examiner. The 687 median days, combined with the 82.3 percent allowance rate, defines the prosecution experience in Art Unit 1624. Practitioners can use the resolved cases to predict future outcomes based on this specific volume of data.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | Non-Final OA | KASHIV BIOSCIENCES, LLC |
| 18665390 | HETEROCYCLIC NLRP3 INHIBITORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | Non-Final OA | BIOMEA FUSION, INC. |
| 18258812 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | Non-Final OA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | Non-Final OA | Gasherbrum Bio, Inc. |
| 18717141 | PYRIMIDINES AND METHODS OF THEIR USE | Non-Final OA | Kineta, Inc. |
| 18717144 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Non-Final OA | Kineta, Inc. |
| 18263656 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | Non-Final OA | ACCUTAR BIOTECHNOLOGY INC. |
| 18702203 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | Non-Final OA | Anvia Therapeutics, Inc.. |
| 18001148 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | Non-Final OA | Saint Louis University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy